Reynolds Oklahoma Center on Aging, Donald W Reynolds Department of Geriatric Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Vasc Med. 2013 Jun;18(3):129-35. doi: 10.1177/1358863X13489768.
We compared plasma apolipoprotein profiles in subjects with peripheral artery disease (PAD) treated with statin medications (n = 21), subjects with PAD who are untreated with statins (n = 18), and control subjects (n = 70). Subjects were assessed on plasma apolipoproteins, medical history, physical examination, ankle-brachial index, and exercise performance using a treadmill test. The percentage of subjects with an abnormal value of apolipoprotein B (ApoB) (≥ 95 mg/dL) was 53% in the PAD group untreated with statins, 29% in the treated PAD group, and 13% in the controls (p < 0.001). The PAD group untreated with statins had higher values for ApoB (p < 0.001), triglycerides (p < 0.01), low-density lipoprotein (LDL)-cholesterol / high-density lipoprotein (HDL)-cholesterol ratio (p < 0.05), and glucose (p < 0.01) than the control group. In contrast, when the statin-treated PAD group was compared with controls, none of the variables were different except that the treated PAD group had lower LDL-cholesterol (p < 0.01) and higher glucose (p < 0.01). Furthermore, the PAD group treated with statins had lower ApoB (p < 0.01), triglycerides (p < 0.001), LDL-cholesterol (p < 0.05), LDL-cholesterol / HDL-cholesterol ratio (p < 0.05), and non-HDL-cholesterol (p < 0.05) than the untreated PAD group. In conclusion, subjects with PAD who are untreated with statin medications have higher levels of ApoB than controls, whereas subjects treated with statins have a more favorable risk profile, characterized by lower ApoB, LDL-C, LDL-C / HDL-C ratio, and non-HDL-C concentrations. Statin therapy may be efficacious for improving apolipoprotein profiles in subjects with PAD and intermittent claudication.
我们比较了接受他汀类药物治疗的外周动脉疾病（PAD）患者（n = 21）、未接受他汀类药物治疗的 PAD 患者（n = 18）和对照组（n = 70）的血浆载脂蛋白谱。通过跑步机测试评估受试者的血浆载脂蛋白、病史、体格检查、踝肱指数和运动表现。未接受他汀类药物治疗的 PAD 组中，载脂蛋白 B（ApoB）异常值（≥95mg/dL）的受试者比例为 53%，接受他汀类药物治疗的 PAD 组为 29%，对照组为 13%（p < 0.001）。未接受他汀类药物治疗的 PAD 组的 ApoB（p < 0.001）、甘油三酯（p < 0.01）、低密度脂蛋白（LDL）-胆固醇/高密度脂蛋白（HDL）-胆固醇比值（p < 0.05）和葡萄糖（p < 0.01）水平均高于对照组。相比之下，当将接受他汀类药物治疗的 PAD 组与对照组进行比较时，除了接受他汀类药物治疗的 PAD 组的 LDL-胆固醇（p < 0.01）和葡萄糖（p < 0.01）水平较低外，其他变量均无差异。此外，与未接受他汀类药物治疗的 PAD 组相比，接受他汀类药物治疗的 PAD 组的 ApoB（p < 0.01）、甘油三酯（p < 0.001）、LDL-胆固醇（p < 0.05）、LDL-胆固醇/HDL-胆固醇比值（p < 0.05）和非-HDL-胆固醇（p < 0.05）水平均较低。总之，未接受他汀类药物治疗的 PAD 患者的 ApoB 水平高于对照组，而接受他汀类药物治疗的患者的风险状况更为有利，其特点是 ApoB、LDL-C、LDL-C/HDL-C 比值和非-HDL-C 浓度较低。他汀类药物治疗可能有助于改善 PAD 和间歇性跛行患者的载脂蛋白谱。
